PsychedelicNewsBreaks

FridaySep 10, 2021 11:50 am

PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Announces Keynote Speaker Chris Ryan, Ph.D., for World’s Premiere Psychedelic and Wellness Event

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, has announced that Chris Ryan, Ph.D., will serve as one of the headline speakers on Nov. 7, 2021, at Meet Delic, the largest and most comprehensive event to learn about the intersection of psychedelics, wellness and business. In his keynote, “Psychedelics and the Search for Truth,” Ryan will explore the emerging potential for psychedelics to reshape the modern world. Ryan is the New York Times best-selling co-author of “Sex at Dawn: How We Mate, Why We Stray, and What it Means for Modern Relationships.” He also hosts…

Continue Reading

ThursdaySep 09, 2021 11:58 am

PsychedelicNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) to Share Company’s Mission, iSTRYM Developments at 2021 SANA Symposium

MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE”), a leader in advanced proprietary technology and research in psychedelics, today announced its presence at the 2021 SANA Symposium as a platinum sponsor and host of the Innovation Theater. According to the update, MINDCURE will be engaging with clinicians around the world interested in learning more about psychedelic-assisted psychotherapy, and specifically in adopting novel protocols and practice standards around psychedelics. The timing of the conference coincides with the company’s recent release of its digital therapeutics (“DTx”) platform for psychedelics — iSTRYM — into partner clinics across North America. “We could not ask for a better time or…

Continue Reading

WednesdaySep 08, 2021 3:18 pm

PsychedelicNewsBreaks – Why Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Is ‘One to Watch’

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, is committed to bringing science-backed benefits to all and reframing the psychedelic conversation. “The Vancouver-based company was formed in 2019 to address the growing interest in psychedelic wellness backed by science. Delic was the ‎first psychedelic umbrella platform. It is currently a trusted source for those interested in ‎psychedelic culture, education, treatments and more,” reads a recent article discussing Delic’s positioning. “While other emerging companies focus on patent medicine and big pharma for substances limited by government regulation, Delic is blazing a unique trail. It identifies ancillary and fully…

Continue Reading

TuesdaySep 07, 2021 2:34 pm

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Positioned as First Mover in Psychedelics Space

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) CEO Greg McKee was recently hosted by Oren Klaff on the Dealmaker Podcast. The interview, which illuminated Tryp Therapeutics’ operations and McKee’s personal story on how he ended up as the CEO, offered some great insights into the future of the psychedelics space, along with what ordinary people can do to take the industry to the next level. A recent article reads, “Mr. McKee cited the benefits that come with the use of psilocybin in treating pain. For one, he discussed their effectiveness without the accompanying risk of addiction associated with opioids. He also…

Continue Reading

FridaySep 03, 2021 11:59 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Featured in Article as Stock That Is ‘Shaping up to Be a Brilliant Investment’

Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company focused on advancing psychedelic pharmaceutical therapeutics for various psychiatric and neurological conditions, was highlighted in a Motley Fool article titled, “Buying Cybin Stock Right Now Could Be a Brilliant Move.” The piece, written by Alex Carchidi, delves into CYBN as one of those investment opportunities in places outside the mainstream. “Cybin (NYSE: CYBN) is a biotech that's developing mental illness treatments derived from widely illegal psychedelic chemicals like psilocybin (best known as the active compound in ‘magic mushrooms’). Based on a swath of extremely positive coverage in the scientific literature,…

Continue Reading

WednesdaySep 01, 2021 11:28 am

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at H.C. Wainwright Global Investment Conference

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, today announced that it will present at the H.C. Wainwright Annual Global Investment Conference. The event is slated to be held virtually on Sept. 13-15, 2021. Greg McKee, chairman and CEO of Tryp, will provide an overview of the company and its pipeline including Tryp's Psilocybin-for-Neuropsychiatric Disorders (“PFN”(TM)) program for chronic pain and eating disorder indications. Interested parties should visit https://ibn.fm/AkhYM to register and access the presentation. In addition, Tryp announced that it has granted an…

Continue Reading

MondayAug 30, 2021 1:46 pm

PsychedelicNewsBreaks – Microdose Psychedelic Insights Announces Upcoming DMT Conference

Microdose Psychedelic Insights, a cutting-edge media company focused on promoting content, financial analysis, and engaging events designed to drive the psychedelics industry into the forefront of modern medicine, will be hosting next month’s DMT Conference. Held in an entirely virtual format, the conference is slated for  Sept. 9–10, 2021. According to the announcement, the event will focus on the potential of dimethyltryptamine (“DMT”) regarding drug development and safety, clinical care, law and regulation, business and markets, science and research. The DMT conference is part of Microdose’s Molecular Masterclasses conference events, a speaker series designed for deep dives into the world's favorite…

Continue Reading

MondayAug 30, 2021 9:30 am

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Releases Part 2 in ‘History of Psychedelics’ Content Series

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, partnered with Visual Capitalist to create a two-part, data-driven content series and graphic that takes a look at how psychedelics have evolved over the last 6,000 years. The second part specifically covers the psychedelic renaissance and digs deeper into what has happened to the psychedelic industry from 2017 to 2020. The two-part series captures key moments in the history of the psychedelic sector, as well as providing a brief outline of  those events and the state…

Continue Reading

FridayAug 27, 2021 11:02 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Eyes Fueled Mission to Develop Revolutionary Psychedelic Therapeutics

Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, in a recent historic move became the first psychedelic biotech company to trade on the NYSE American LLC stock exchange. “We are all delighted to receive this approval from the NYSE American and are thankful to our wonderful team and loyal investor base who have followed us on this journey so far,” an article quoted Cybin CEO Doug Drysdale discussing the milestone. “As the first psychedelic biotech company that will now trade on this esteemed exchange in the U.S., we will…

Continue Reading

FridayAug 27, 2021 9:39 am

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Featured in Equity Research Report

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, was featured in a recent equity research report. The coverage, initiated by Ladenburg Thalmann & Co. Inc., highlights Tryp Therapeutics’ efforts to reset the treatment of various disorders through the novel dosing of formulations of synthetic psilocybin. “We are initiating coverage on Tryp Therapeutics with a Buy rating and $2.00 price target based on our research into its psychedelic-based pipeline, which is leveraging psilocybin’s potential to treat patients with inadequately addressed neurological disorders. The company is on track to test…

Continue Reading